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Acetaminophen Combinations Protect Against
Iron-Induced Cardiac Damage in Gerbils

Ernest M. Walker, Jr.,1,2 Ryan G. Morrison,6 Lucy Dornon,2 Joseph P. Laurino,9 Sandra M. Walker,7
Mark Studeny,2,10 Paulette S. Wehner,2,10 Kevin M. Rice,3-5 Miaozong Wu,5 Eric R. Blough,3-5,8
1Pathology, 2Cardiovascular Services, 3Pharmacology, Physiology, & Toxicology, 4Biological Sciences,
5Cell Differentiation & Development Center, 6School of Medicine, 7Community & Technical College,
8College of Education & Human Services, all at Marshall University, Huntington, WV; 9Chemistry
Department, University of Tampa, Tampa, FL; and 10St. Mary’s Medical Center, Huntington, WV
Abstract. This study tested if acetaminophen, N-methyl-D-glucamine dithiocarbamate (NMGDTC),
deferoxamine, and combinations of these agents reduce excess iron content, prevent iron-induced pathology,
reduce cardiac arrhythmias, and reduce mortality in iron-overloaded gerbils. Eight groups of 16 gerbils
received iron dextran injections (ferric hydroxide dextran complex, 120 mg/kg, ip) or saline solution
(controls) twice/wk for 8 wk. The 8 groups were treated every Monday, Wednesday, and Friday with one of
the following: saline control, acetaminophen, 150 mg/kg, ip), acetaminophen (150 mg/kg, po), deferoxamine,
83 mg/kg, ip), NMGDTC (200 mg/kg, ip), or combinations of acetaminophen (75 mg/kg) with
deferoxamine (42 mg/kg, each ip, separately) or acetaminophen (75 mg/kg) with NMGDTC (100 mg/kg,
each ip, separately). The treatments were given 4 hr after each iron injection on days when both iron
administration and treatment occurred during iron overloading (8 wk) and were continued 4 wk thereafter.
Echocardiography (ECHO) was used to evaluate iron-induced cardiac changes and detect arrhythmias.
Acetaminophen and NMGDTC, or combinations thereof, reduced cardiac and hepatic excess iron content
as measured by inductively coupled plasma atomic emission spectrometry (ICP-AES). Acetaminophen was
effective whether administered po or ip. Acetaminophen treatment had a positive inotropic effect on cardiac
function. Acetaminophen-deferoxamine combination conferred equal cardioprotection as acetaminophen
or deferoxamine alone, was equally able to remove hepatic iron, and was superior to either acetaminophen
or deferoxamine in removing cardiac iron from iron-overloaded gerbils. Acetaminophen-NMGDTC
combination was also effective in removing cardiac and hepatic iron and protecting against iron-induced
cardiac damage. ECHO evaluation of iron-overloaded, untreated gerbils demonstrated a high incidence of
cardiac arrhythmias, usually PVCs (10/16 = 63%), and mortality prior to completion of the experiment
(4/16 = 25%). All treatments except deferoxamine, alone, reduced the incidence of cardiac arrhythmias
and deaths. All treatments reduced iron-induced increases in hepatic and cardiac weights. This study
demonstrates injection alternates that are equally or more effective than deferoxamine injections and shows
oral acetaminophen to be effective in treatment of iron-overload and associated cardiac complications.
Keywords: iron-overload, acetaminophen, deferoxamine, N-methyl-D-glucamine dithiocarbamate
Introduction
Address correspondence to Ernest M. Walker, Jr., M.D.,
Ph.D., Department of Pathology, Joan C. Edwards School of
Medicine, Marshall University, 1542 Spring Valley Drive,
Huntington, WV 25704, USA; tel 304 654 9580; fax 304
696 6777; e-mail walkere@marshall.edu.

More than two million persons in the United States
and up to one hundred million persons worldwide
have some degree of iron-overload and tissue
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accumulation of the metal [1]. It is estimated that
nearly 40 million people worldwide have severe
iron-overload. There are two major categories of
conditions causing iron-overload: (a) hereditary
hemochromotosis, an autosomal recessive disorder
with a frequency of about 10% in individuals of
European descent [2-4], and (b) various types of
hemosiderosis involving RBC destruction and
requiring blood transfusions [5]. In these cases,
tissue iron levels progressively increase with age
and may cause life-threatening complications.
These include advanced liver disease and cirrhosis,
diabetes mellitus due to iron accumulation in
pancreatic islets with damage to beta cells, and
cardiotoxicity due to iron deposits in myocytes,
interstitial cells of the myocardium, and within the
fibers of the conduction system. Cardiotoxic effects
may be severe with cellular degeneration and
fibrosis of the myocardium, disturbances of cardiac
rhythm, and eventual death. Individuals with only
mild to moderate elevations in tissue iron content
appear to have increased risk for developing diabetes
mellitus, heart disease, gastrointestinal cancers,
and hematological malignancies [1].
Treatment with phlebotomy results in clinical
improvement of subjects with established elevations
in tissue iron burden and, if used as a preventative
therapy, may lessen or ameliorate organ damage
and allow normal life expectancy [1,6]. However,
this treatment requires weekly removal of up to a
liter of whole blood for a year or longer, followed by
lifetime maintenance phlebotomy. Therapy with
currently approved chelating agents is presently a
poor substitute for phlebotomy and is used mainly
in patients with secondary hemochromatosis or
hemosiderosis. Deferoxamine (Desferal,® Novartis),
deferiprone (L1), and deferasirox (Exjade,® Novartis)
are the major chelating agents currently used to
treat iron overload. Deferoxamine has been used
for many years, but it must be administered by
parenteral routes and is associated with adverse
effects and low compliance [5, 7]. L1 (1, 2-dimethyl3-hydroxypyridin-4-one), a once promising orally
active iron chelator, appears to be ineffective [8] or
contraindicated [9] in many patients. Deferasriox
has recently been approved to treat iron-overloaded
patients. It is orally effective and its long half-life
enables once-daily dosing [10,11]. At present there

is a great clinical need for additional, orally active
iron chelating drugs for treating iron overload.
Previous studies in our laboratory [12,13]
demonstrated that injections of acetaminophen
and deferoxamine are equally effective in reducing
cardiac excess iron content in iron-overloaded
gerbils, and preventing cardiac structural and
functional changes. This paper reports concurrent
studies of iron-overloaded gerbils, not published in
the original paper [12], which show that injections
of acetaminophen, deferoxamine, or N-methyl-Dglucamine dithiocarbamate (NMGDTC), as well
as combinations of acetaminophen with deferoxamine or NMGDTC reduce the excess iron content
in heart and liver and protect against iron-induced
cardiotoxicity in iron-overloaded gerbils.
Materials and Methods
Chemicals. Ferric hydroxide dextran complex (Sigma
Chemical Co., St Louis, MO) dissolved in NaCl solution
(1%, w/v) was used for iron overloading. The treatment agents
were: (a) acetaminophen (Sigma), (b) deferoxamine methanesulfonate (Sigma), and (c) NMGDTC, synthesized as
described [14] and supplied by Dr. Mark M. Jones (Vanderbilt
University, Nashville, TN).
Animals. Mongolian golden gerbils (Hilltop Laboratories,
Scottsdale, PA; male; age 12 wk; average initial weight ~60 g)
were housed on wood chip bedding in plastic tubs at 23 ± 2°C
in rooms with a 12 hr light/dark cycle. Purina gerbil chow
and tap water were available ad libitum. All procedures with
animals were approved by the Marshall University Institutional
Animal Care and Use Committee.
Treatments. The gerbils were divided into 8 groups of 16
animals: (a) saline controls (SC) received injections of 1%
saline (0.15 ml/kg, ip) twice/wk for 8 wk; (b) iron-overloaded
animals (IO) received similar injections of iron dextran in 1%
saline (120 mg/kg, ip, twice/wk); (c) iron-overloaded treated
with acetaminophen (150 mg/kg, ip, IOAi); (d) ironoverloaded treated with acetaminophen (150 mg/kg, po,
IOAo); (e) iron-overloaded treated with deferoxamine (83
mg/kg, ip, IODF); (f) iron-overloaded treated with NMGDTC
(200 mg/kg, ip, IONMG); (g) iron-overloaded treated with
half-doses of acetaminophen (75 mg/kg) and deferoxamine
(42 mg/kg) given separately as ip injections (IOA0.5NMG0.5);
and (h) iron-overloaded treated with half-doses of acetaminophen (75 mg/kg) and NMGDTC (100 mg/kg) given
separately as ip injections (IOA0.5DF0.5). The saline and
iron dextran solutions were injected twice/wk for 8 wk. The
acetaminophen, deferoxamine, NMGDTC, and combinations
were administered thrice/wk (every Monday, Wednesday, and
Friday). When an iron dextran injection and drug treatment
fell on the same day, the treatment was administered 2 to 4 hr
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after the iron dextran. The treatments followed this schedule
for 8 wk and were continued for an additional 4 weeks (total
of 12 wk of treatment). Echocardiograms were performed on
gerbils at 12 wk after the last treatment.
Echocardiography (ECHO). ECHO studies were conducted
on gerbils anesthetized by ip injection of a 2:1 (v/v) mixture of
ketamine HCl (100 mg/ml) and xylazine (20 mg/ml). The
ECHO studies used a Phillips Sonos 5500 echocardiogram
with a S12 transducer (frequency range 8-12 MHz) as
described previously [12]. Echocardiographic images were
obtained including two-dimensional, pulse-wave Doppler
and M-mode images. Functional and structural parameters
were evaluated as described previously [12,14].
Tissue iron analysis. After completion of the echocardiograms,
the gerbils were euthanized by inhalation of CO2 . The hearts
and livers were removed by dissection, weighed, frozen in
liquid nitrogen, and stored at -70°C until analysis. Whole
hearts and liver samples (300-400 mg) were digested at 37°C
for 6 or 17 hr in glass digestion tubes containing concentrated
ultrapure nitric and perchloric acids (30:70, v/v, total volume
10 ml). A 1.67 mg/L iron solution was used as a digestate
control. Yttrium solution (1,000 mg/L) in 2% HNO3 was
added to each tube and served as an internal standard (final
concentration, 1.67 mg/L). After digestion, 5.0 ml of each
digestate was transferred to a 50 ml volumetric flask and
brought to volume with 2% HNO3 (ultrapure). The solutions
were filtered through 0.22 µm syringe-driven filter units
(Millipore). Tissue iron concentrations were determined by
inductively coupled plasma/atomic emission spectrometry
(ICP-AES), using an Optima 2100 apparatus (Perkin-Elmer,
Norwalk, CT; 238 and 204 nm). Standard curves (0 to 1; 0 to
10; 0 to 100 mg Fe/L) were prepared depending on the tissue
iron concentrations [15-18] and the results were reported as
mg Fe/entire liver or µg Fe/entire heart.
Statistics. Data were expressed as mean ± SD. Statistical
analyses were performed using Sigma Stat software (Jandel
Corp., San Rafael, CA). Differences among the means of the
groups were assessed by two-way ANOVA, followed by
Tukey’s test. Values of p ≤0.05 were considered significant.

Results
Effects on cardiac and liver iron. Injections ip of
acetaminophen, deferoxamine, or NMGDTC,
alone, and acetaminophen-deferoxamine or acetaminophen-NMGDTC combinations reduced the
excess cardiac and hepatic iron contents (Fig. 1).
Oral administration of acetaminophen also reduced
tissue iron content and ameliorated cardiac effects.
The post-treatment hepatic iron contents were: SC,
0.24 ± 0.02 mg; IO, 49.05 ± 1.46 mg; IOAi, 37.40
± 6.78 mg; IOAo, 33.98 ± 6.34 mg; IODF, 20.20 ±
1.64 mg; IONMG, 18.31 ± 1.07 mg; IOA0.5-

Fig, 1. The iron content of liver (mg/entire liver) (panel A) and
heart (µg/entire heart) (panel B) of saline controls (n = 13),
and gerbils that were iron overloaded (IO, n = 13),
acetaminophen injected (IOAi, n = 9), acetaminophen
administered by oral gavage (IOAo, n = 10), deferoxamine
injected (IODF, n = 7), NMGDTC injected (IONMG, n =
8), acetaminophen (half-dose) plus NMGDTC (half-dose)
injected (IoAiNMG, n = 8), and acetaminophen (half-dose)
plus deferoxamine (half-dose) injected (IOAiDF, n = 8). The
* or + indicate significant differences (p <0.05) from the
controls or iron overloaded gerbils, respectively.

NMG0.5, 18.93 ± 1.93 mg ; IOA0.5DF0.5, 18.24 ±
1.04 mg. The post-treatment cardiac iron contents
were: SC, 15.11 ± 11.77 µg; IO, 243.36 ± 51.08 µg;
IOAi, 130.38 ± 29.58 µg; IOAo, 131.76 ± 26.62
µg; IODF, 110.50 ± 7.47 µg; IONMG, 106.34 ±
10.59 µg; IOA0.5NMG0.5, 101.39 ± 12.36 µg;
IOA0.5DF0.5, 88.53 ± 9.21 µg. The average posttreatment cardiac iron concentrations per g of heart
were: SC, 43.17 ± 27.81 µg; IO, 552.27 ± 58.12 µg;
IOAi, 395.09 ± 88.10 µg; IOAo, 387.52 ± 66.44
µg; IODF, 324.99 ± 23.95 µg; IONMG, 304.00 ±
17.40 µg; IOA0.5NMG0.5, 316.84 ± 59.04 µg;
IOA0.5DF0.5, 268.27 ± 25.38 µg.
The best results for cardiac iron removal were
produced by the ip injection combination of halfdoses of acetaminophen (75 mg/kg) and deferoxamine (42 mg/kg) (IOA0.5DF0.5), which removed

Acetaminophen combinations remove excess iron from gerbils 381
Table 1. Echocardiographic evaluation of cardiac structural parameters in gerbils.
Group
N
		
Control
IO
IOAi
IOAo
IODF
IONMG
IOAiNMG
IOAiDF

16
15
9
10
7
8
8
8

IVSd
(cm)

IVSs
(cm)

LVIDd
(cm)

0.09 ± 0.01
0.13 ± 0.01*
0.09 ± 0.01+
0.09 ± 0.02+
0.10 ± 0.01+
0.11 ± 0.01+
0.08 ± 0.02+
0.10 ± 0.01+

0.15 ± 0.01
0.19 ± 0.01*
0.14 ± 0.01+
0.15 ± 0.02+
0.15 ± 0.01+
0.16 ± 0.02+
0.13 ± 0.02+
0.15 ± 0.01+

LVIDs
(cm)

0.43 ± 0.01
0.27 ± 0.01
0.53 ± 0.02* 0.35 ± 0.01*
0.44 ± 0.01+ 0.30 ± 0.01*,+
0.48 ± 0.02+ 0.31 ± 0.02*,+
0.43 ± 0.02+ 0.27 ± 0.01+
0.44 ± 0.02+ 0.30 ± 0.03+
0.49 ± 0.06 0.32 ± 0.04
0.46 ± 0.05 0.32 ± 0.03

LVPWd
(cm)

LVPWs
(cm)

RV
(cm)

0.11 ± 0.01
0.17 ± 0.01*
0.11 ± 0.01+
0.10 ± 0.01+
0.12 ± 0.01+
0.12 ± 0.02+
0.12 ± 0.02+
0.12 ± 0.02+

0.14 ± 0.01
0.19 ± 0.01*
0.15 ± 0.01+
0.16 ± 0.02+
0.15 ± 0.01+
0.16 ± 0.02+
0.16 ± 0.02+
0.15 ± 0.02+

0.14 ± 0.01
0.20 ± 0.01*
0.12 ± 0.01+
0.12 ± 0.02+
0.14 ± 0.01+
0.15 ± 0.03+
0.11 ± 0.01+
0.12 ± 0.03+

An asterisk (*) or cross (+) indicates significant difference (p <0.05) from control and iron-overloaded (IO) gerbils, respectively.
N, number of gerbils in the group; IVSd, diastolic LV septal thickness; IVSs, systolic LV septal thickness; LVIDd, diastolic
LV internal thickness; LVIDs, systolic LV internal thickness; LVPWd, diastolic LV posterior wall thickness; LVPWs, systolic
LV posterior wall thickness; RV, RV diastolic internal dimension.

Table 2. Echocardiographic evaluation of cardiac functional parameters in gerbils.
Group
Control
IO
IOAi
IOAo
IODF
IONMG
IOAiNMG
IOAiDF

EF
(%)

FS
(%)

AV Max
(cm/sec)

PV Max
(cm/sec)

MV Max
(cm/sec)

MV Max
(cm/sec)

77.5 ± 1.5
60.6 ± 1.8*
72.5 ± 1.7*,+
76.4 ± 1.7+
67.1 ± 1.1*,+
69.6 ± 5.0*,+
70.4 ± 4.0*
64.8 ± 10.4*

40.4 ± 1.5
27.9 ± 1.3*
35.0 ± 2.0*,+
39.3 ± 1.3+
34.1 ± 2.4*,+
34.0 ± 3.7*,+
34.8 ± 3.2*
29.7 ± 7.3*

47.2 ± 2.5
49.8 ± 2.4
70.4 ± 4.0*,+
58.6 ± 3.3*,+
53.4 ± 3.9
54.9 ± 9.6
60.2 ± 8.2+
48.6 ± 6.6

48.9 ± 3.2
52.9 ± 4.2
66.2 ± 4.4*,+
58.1 ± 4.0*
47.6 ± 3.2
45.9 ± 6.1
57.1 ± 5.0
44.7 ± 5.0

41.0 ± 3.9
38.0 ± 3.7
50.7 ± 2.9*,+
44.3 ± 3.4
39.8 ± 3.2
----------------------------

40.3 ± 2.6
38.1 ± 3.1
51.0 ± 4.0*,+
37.0 ± 1.8
37.6 ± 2.3
----------------------------

An asterisk (*) or cross (+) indicates significant difference (p <0.05) from control and iron overloaded (IO) gerbils, respectively.
EF, ejection fraction; FS, left ventricular fractional shortening during systole; AV Max, maximal aortic valvular blood flow
velocity; PV Max, maximal pulmonary valvular blood flow velocity; MV Max, maximal mitral valvular blood flow velocity; TV
MAX, maximal tricuspid valvular blood flow velocity.

Table 3:

Body weights, liver weights/body weights, and heart weights/body weights of the gerbils.

Group

Body wt.
(g)

Liver wt./body wt.
(%)

Heart wt./body wt.
(%)

Control
IO
IOAi
IOAo
IODF
IONMG
IOAiNMG
IOAiDF

83.7 ± 2.2
66.9 ± 2.6
85.3 ± 2.4
84.2 ± 2.3
92.6 ± 5.6
85.5 ± 2.7
84.4 ± 4.5
92.3 ± 2.3

3.77 ± 0.46
7.80 ± 0.86*
5.44 ± 0.36*,+
5.14 ± 0.20*,+
4.78 ± 0.28*,+
5.23 ± 0.22*,+
5.11 ± 0.12*,+
4.25 ± 0.05*,+

0.41 ± 0.03
0.65 ± 0.12*
0.43 ± 0.04+
0.40 ± 0.01+
0.37 ± 0.01+
0.39 ± 0.03+
0.39 ± 0.03+
0.33 ± 0.02*,+

Average group and organ/body weights at the end of the experiments. An asterisk (*) or cross (+) indicates significant difference
(p <0.05) from control and iron overloaded (IO) gerbils, respectively. See Materials and Methods for abbreviations.
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significantly more cardiac iron (p <0.05) than was
removed by full-dose injections of either acetaminophen (150 mg/kg) or deferoxamine (83 mg/kg)
alone. The cardiac iron removal produced by the
combination of half-doses of acetaminophen and
NMGDTC (100 mg/kg) (IOA0.5EY0.5) was not
significantly greater than that removed by fulldoses of either agent alone. Combinations of halfdoses of acetaminophen and deferoxamine
(IOA0.5DF0.5) removed slightly more hepatic iron
than either agent alone, but the results were not
significant when compared to deferoxamine alone.
Echocardiographic studies. The ECHO results for
control, iron-overloaded, iron-overloaded-acetaminophen-treated and iron-overloaded-deferoxamine-treated gerbils are reported in Tables 1 and
2 and in the earlier publication [12]. Ironoverloading affected structural parameters of the
heart, increased total cardiac weight, and produced
cardiac hypertrophy as shown by increased septal,
left ventricular, and right ventricular wall
thicknesses. These changes were abrogated by treatments with acetaminophen or its combinations.
Cardiac function was evaluated by measurements of ejection fraction (EF) and left ventricular
shortening during systole (FS), as well as blood
flow velocities through cardiac valves. Hearts from
iron-overloaded gerbils demonstrated reductions in
EF and FS consistent with appreciable compromise
of cardiac function. Acetaminophen, given orally
or by injection, prevented these changes or restored
cardiac function to values similar to untreated
controls. An interesting result of acetaminophen
treatment was increased blood flow rates through
cardiac valves (aortic, pulmonary, mitral, tricuspid)
(Table 2), which suggest a positive inotropic effect
conferred by injected acetaminophen. This finding
may be important and merits further study.
ECHO studies were concurrently completed
for the iron-overloaded-acetaminophen (75 mg/kg)
plus deferoxamine (42 mg/kg), iron-overloaded–
NMGDTC (200 mg/kg), and iron-overloadedNMGDTC (100 mg/kg) plus deferoxamine (42
mg/kg) groups. The results demonstrate cardioprotection against the iron-induced functional and
structural changes similar to the protection
provided by acetaminophen alone (Tables 1 & 2).

Arrhythmias and mortality. During the total
period of observation of the 16 saline controls (SC),
none developed cardiac arrhythmias (ECHO
studies) and there were no deaths. Of 16 ironoverloaded gerbils, 10 developed significant cardiac
arrhythmias, ie, chiefly premature ventricular
contractions (PVCs), and 4 of the 16 gerbils died
after completion of ECHOs and prior to the end of
the experiment. Nine of 16 iron-overloaded gerbils
treated by acetaminophen, ip (IOAi) were evaluated
by ECHO and showed 0 cardiac arrhythmias
(ECHO) and 1 death. Ten of 16 iron-overloaded
gerbils treated orally with acetaminophen (IOAo)
were evaluated by ECHO and demonstrated 1
animal with cardiac arrhythmia (PVCs) and 0
deaths. Seven of the 16 iron-overloaded gerbils
treated with deferoxamine ip were evaluated by
ECHO and 3 animals showed cardiac arrhythmias
(PVCs), and died prior to the end of the experiment.
Eight of 16 NMGDTC injected gerbils were
evaluated by ECHO and there was 1 animal with
cardiac arrhythmia and 1 death (same animal).
Eight of 16 animals treated with half-doses of
acetaminophen plus half-doses of deferoxamine
were evaluated by ECHOed and 1 animal
demonstrated cardiac arrhythmia but 0 deaths.
Eight of 16 gerbils treated with half-doses of
acetaminophen plus half-doses of NMGDTC and
evaluated by ECHO showed 1 animal with cardiac
arrhythmia but there were 0 deaths. All treatments
except deferoxamine produced appreciable
reductions in the incidence of iron-induced cardiac
arrhythmias and mortality.
Iron overloading was very toxic to the gerbils.
Iron overloading caused a high incidence of
arrhythmias (10/16), mortality (4/16), suppression
of weight gain, and increased heart and liver weights
as shown in Table 3. Initial body weights of the
gerbils averaged about 60 g. All groups except the
untreated iron-overloaded gerbils showed weight
increases of 20 g or more at 12 wk. The untreated
iron-overloaded group gained an average of ~7 g.
Discussion
Acetaminophen is a frequently used non-steroidal
anti-inflammatory analgesic agent. Deferoxamine
is an established iron-removing agent with great
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effectiveness when administered parenterally.
NMGDTC is a substituted dithiocarbamate (LD50
>2 g/kg in mice) that has been reported to combat
the platinum toxicity seen in the use of cisplatin in
cancer chemotherapy [19]. It has also been shown
to have iron-chelating ability [20,21]. Results of
this study demonstrate that it has a similar ability
as deferoxamine and acetaminophen in removing
cardiac and liver iron from iron-overloaded gerbils.
NMGDTC was able to prevent or reverse ironinduced cardiac structural changes and improve
iron-induced decline in EF and FS (Tables 1 & 2).
However, NMGDTC is unstable in an acid (gastric)
environment so that it has limited effectiveness
when administered orally.
Injections of acetaminophen, acetaminophendeferoxamine combination, NMGDTC, or acetaminophen-NMGDTC combination reduced the
tissue iron contents without producing appreciable
signs of toxicity or drug-related deaths. This is
consistent with a study in rats in which daily oral
(gavage) doses of acetaminophen (200 mg/kg for
200 days) failed to induce any significant changes
when compared to controls [22]. In a similar study,
male C57BL/6J mice received acetaminophen (30
or 300 mg/kg). The higher dose up-regulated 6
genes and down-regulated 18 genes when evaluated
24 hr after the injection of acetaminophen. The
acetaminophen effects on gene expression serve as
markers of mild hepatotoxicity, but no histological
findings of hepatic necrosis or other hepatotoxicity
were noted [23]. Results of our acetaminophendeferoxamine or acetaminophen-NMGDTC
combination studies show that the lower dose of
acetaminophen is effective in combinations, thus
providing a greater safety margin for the drug in
treatments.
A previous study demonstrated that injections
of acetaminophen and deferoxamine are equally
effective in reducing cardiac excess iron content
and preventing cardiac structural and functional
changes as assessed by ECHO studies [12]. In the
present study, the ECHO techniques demonstrated
that acetaminophen-deferoxamine combination
conferred equal cardioprotection as acetaminophen
or deferoxamine alone. The combination
demonstrated a similar ability to remove hepatic
iron, and superior ability to either acetaminophen

or deferoxamine in removing cardiac iron from
iron-overloaded gerbils. NMGDTC alone and
acetaminophen-NMGDTC combination were as
effective as deferoxamine in removing hepatic and
cardiac iron (Fig. 1). NMGDTC was particularly
impressive in preventing iron-induced cardiac left
ventricular and right ventricular structural changes
(Table 1) to a degree similar to that produced by
acetaminophen. Half-dose combination of injected
acetaminophen and NMGDTC reduced ironinduced alterations in right ventricular structure
but were slightly less effective than NMGDTC or
acetaminophen in preventing left ventricular
structural changes. The finding that NMGDTC
reduced or prevented iron-induced cardiac
functional changes while removing excess cardiac
and hepatic iron suggests that this compound is a
potential agent for treating iron overload.
Congestive cardiomyopathy is the most
common defect that occurs with iron overload, but
pericarditis, restrictive cardiomyopathy, and angina
without coronary artery disease have been reported
[24-27]. Iron deposition in the bundle of His and
the Purkinje system produces conduction defects
and may cause fatal arrhythmias [28,29]. Physical
examination may fail to disclose cardiac toxicity,
but cardiac failure may occur suddenly, with rapid
deterioration without medical intervention.
Biventricular heart failure produces pulmonary
congestion, peripheral edema, and hepatic
engorgement. Vigorous iron extrication can reverse
this potentially lethal complication [30].
Echocardiography in children and radionuclide
ventriculography in adults are the most useful noninvasive diagnostic techniques. Exercise radionuclide
ventriculograms are particularly sensitive in the
detection of cardiac dysfunction in patients with
iron overload [31]. These techniques can be used
periodically to evaluate therapeutic responses
during treatments such as chelation. In our study,
echocardiography and electrocardiography were
used to follow cardiac improvement induced by the
acetaminophen or combination treatments.
Electrocardiography was used in conjunction with
echocardiography to detect the development and
prevention or reversal of iron-induced cardiac
arrhythmias. A strong correlation exists between
the cumulative number of blood transfusions and
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functional cardiac derangements in children with
thalassemia [32,33], so that the echocardiographic
abnormalities correlate roughly with the number of
transfusions or degree of cardiac iron overload.
Effects of iron on cardiomyocyte contractility
have been documented. Iron salts added to cultures
of chick cardiac cells poison the cells and impede
their ability to contract spontaneously.
Deferoxamine restores myocyte contractility
through chelation of extracellular and intracellular
iron [34].
Cardiac dysfunction can occur with little tissue
iron deposition. The total quantity of iron is less
important than the unbound “toxic” iron subset.
The concentration of unbound iron in tissues is
extremely small and virtually impossible to
measure. This “toxic” iron is the component bound
and neutralized by iron chelators. Therefore, cardiac
damage is best prevented in patients with
transfusional iron overload by maintaining a
constant low level of chelator in the circulation and
tissues [12,35]. Early use of deferoxamine in an
amount proportional to the transfusional iron load
reduces the body iron burden and helps protect
against diabetes mellitus, cardiac disease, and early
death in patients with thalassemia major [36].
In conclusion, this study shows that NMGDTC
is capable of reducing cardiac and liver iron content
in iron-overloaded gerbils, combating iron-induced
cardiac structural and functional changes, and
reducing iron-induced hepatic weight increases.
NMGDTC is effective when administered alone,
or combined with acetaminophen. Acetaminophen
shares with deferoxamine the abilities to remove
cardiac and hepatic iron, restore contractility, and
prevent iron-induced cardiac structural and
functional deterioration. Acetaminophen offers a
number of distinct advantages: (a) it provides a
potential treatment of iron overload with an orally
effective agent; (b) its iron-removing effectiveness is
equal to or greater than established agents such as
deferoxamine, which has to be injected; (c)
acetaminophen can be used concurrently with
other agents with additive or synergistic effects,
allowing the use of lower doses of the agents; (d)
acetaminophen protects the heart against ironinduced cardiac structural changes by preventing
iron-induced increases in total heart mass and

preventing or reversing iron-induced increases in
heart LV and RV thicknesses; (e) acetaminophen
prevents or reverses iron-induced impairment in
cardiac function, as shown by restoration of FS and
EF to values similar to saline controls; (f)
acetaminophen appears to decrease the incidence
of life-threatening arrhythmias, a common cause
of death, and may combat other iron-induced
cardiac complications such as congestive
cardiomyopathy; and (g) acetaminophen may have
positive inotropic effects on cardiac function, a
finding that should be investigated further.
Based on our previous work [12], we speculate
that acetaminophen may provide cardioprotection
by two different but related mechanisms: its
antioxidant effects and by removal of excess cardiac
iron concentrations. Deferoxamine and NMGDTC
may provide cardioprotection by the same two or
by different mechanisms. The iron-removing ability
of acetaminophen-deferoxamine combination is
superior to that of either agent alone. The antioxidant characteristics of acetaminophen might
provide cardioprotection and prevent tissue or
organ damage in various conditions that involve
increased iron concentrations and that induce the
release of free radicals and other oxidants [1]. It is
interesting to speculate that combinations of
acetaminophen and deferasirox, a recently approved
oral agent for treating transfusional iron overload,
both orally effective, might offer advantages over
that of either agent. Our future studies may address
this possibility.
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